And then for a slightly more up-to-date situational analysis: the company has turned out to be a disappointment in my case. Schedules are slipping and there is still no information about the clinical trial. I would estimate that new share issues will be arranged by May at the latest, before the summer holidays. Unless a licensing agreement comes as a surprise before then.
According to the investor letter published yesterday, the “design freeze” for the device is still not completed and improvements are being worked on. However, for the assay unit itself and its reagents, this was achieved in December.
